Kojie Pharmacy-B (02171.HK) plans to hold a board of directors meeting on August 28 to approve its interim performance.
Kaiji Pharmaceutical-B (02171.HK) announced on August 15th that the board of directors meeting will be held on Wednesday, August 28th, 2024, to consider and approve the group's interim performance for the six months ending June 30th, 2024, as well as to handle other matters.
CARSGEN-B: DATE OF BOARD MEETING
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
On June 28, Keji Pharmaceutical -B (02171.HK) spent HKD 720,000 to repurchase 150,000 shares.
On June 28th, Keji Pharmaceutical -B (02171.HK) announced that it had spent HKD 720,000 to repurchase 150,000 shares.
CARsgen Therapeutics' Substantial Shareholder Boosts Stake to 37.78%
Kangji Pharmaceutical (02171) under Hong Kong Stock Connect: the major shareholder has increased shareholding by 1.9 million shares, and the company has repurchased 3.98 million shares.
Jingu Finance News | Koji Pharmaceutical (02171) announced that the board of directors was informed by Yijie Biology that the Yijie concerted action group has purchased a total of 1.9035 million shares of the company's stock within this year until June 25, 2024 (after the close of trading), accounting for approximately 0.33% of the total issued shares. After increasing its shareholding, the Yijie concerted action group holds 217 million shares of the company's stock, accounting for approximately 37.78% of the total issued shares. In addition, as of the close of trading on June 25, 2024, the company has repurchased a total of 3.9855 million shares of its own stock, accounting for approximately 0.69% of the total issued shares. The funds used to repurchase the shares are from...
Keji Pharmaceutical-B (02171.HK): Yijie Joint Action Group has purchased a total of 1.9035 million shares.
On June 27th, Keji Pharmaceutical-B (02171.HK) announced that the board of directors had been informed by the company's major shareholder, Yijie Biotechnology Holdings Limited ("Yijie Biotechnology"), that Yijie Biotechnology and its concerted action parties ( collectively referred to as the "Yijie concerted action group") plan to acquire the company's shares on the public market within about twelve months from the date of the announcement. The board of directors was recently informed by Yijie Biotechnology that the Yijie concerted action group has purchased a total of 1.9035 million shares, accounting for approximately 0.33% of the total issued shares from the beginning of this year to the close of June 25th, 2024. After increasing the shareholding, Yijie.
Express News | CARsgen Therapeutics - After Shareholding Increase, Yijie Concert Group Holds 37.78% of Total Issued Shares of Co
Express News | CARsgen Therapeutics - Informed by Yijie Biotech That Yijie Concert Purchased 0.33% of Total Issued Shares of Co Within This Year up to June 25
On June 25th, Keji Pharmaceutical -B (02171) spent HKD 716,150 to repurchase 145,500 shares.
Keji Pharmaceutical -B (02171) announced that it will spend 716,150 Hong Kong dollars to repurchase 14...
Statistics on abnormal proportion of CITIC Securities Hong Kong Stock Connect on June 21st.
Statistics on the abnormal proportion of CITIC HK Stock Connect on June 20, 2024.
Keji Pharmaceutical B (02171) spent HKD 6.3738 million on June 20th to repurchase 1.1 million shares.
Keji Pharmaceutical -B (02171) announced that on June 20, 2024, the company spent 6.3738 million Hong Kong dollars to repurchase 1.1 million shares, with a repurchase price per share of 5.61-5.8 Hong Kong dollars.
On June 19, Keji Pharmaceutical -B (02171.HK) spent HKD 3.98 million to repurchase 700,000 shares.
On June 19th, Keji Pharmaceutical-B (02171.HK) announced the repurchase of 700,000 shares for HKD 3.98 million.
On June 18, Koji Pharmaceutical spent approximately HKD 748,100 to repurchase 139,500 shares.
SciClone Pharmaceuticals B (02171) announced that it will spend approximately HKD 748,100 to repurchase 139,500 shares on June 18, 2024, with a repurchase price of HKD 5.24-5.42 per share.
On June 18th, Keji Pharmaceutical -B (02171.HK) bought back 139,500 shares for HKD 748,000.
On June 18th, Koji Pharmaceuticals-B (02171.HK) announced that it spent HKD 748,000 to buy back 139,500 shares.
Keji Pharmaceutical-B (02171.HK) presented updated research results on the Phase II clinical trial of Saikai II and the first human trial of CT071 at the 2024 EHA annual meeting.
On June 17, Gelunhui announced that the updated results of Saikai Xi (Zevo Kyolun Race Injection, product number: CT053, a self-targeting CAR-T cell product targeting BCMA) and CT071 (a self-targeting CAR -T cell candidate product targeting G protein-coupled receptor C group 5 member D (GPRC5D)) were reported at the 29th European Hematology Association ("EHA") Annual Meeting. The results of the Lumicar Study 1 of Saikai Xi have been reported on Central European Summer Time 2024.
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024
On June 14, Keji Pharmaceutical B (02171) spent approximately HKD 2.3217 million to repurchase 397,500 shares.
Kehao Pharmaceutical-B (02171) announced that it will spend about 2.3217 million Hong Kong dollars on June 14, 2024...
On June 13th, Keji Pharmaceutical-B (02171.HK) spent HKD 28,700 to repurchase 5,000 shares.
On June 13th, Keji Pharmaceutical - B (02171.HK) announced the repurchase of 5,000 shares for HKD 28,700.
On June 12th, Keji Pharmaceutical spent HKD 580,900 to repurchase 104,000 shares.
Kee Jie Pharmaceutical-B (02171) announced that on June 12, 2024, the company spent HKD 580,900 to repurchase 104,000 shares, with a repurchase price of HKD 5.56-5.6 per share.
No Data